Skip to main content

Burns

21
Pipeline Programs
30
Companies
50
Clinical Trials
2 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
4
1
1
2
8
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 47 programs with unclassified modality

On Market (3)

Approved therapies currently available

Pfizer
GENOTROPINApproved
somatropin
Pfizer
injection1995
27M Part D
Bayer
CIPROApproved
ciprofloxacin
Bayer
oral1997
396K Part D
Pfizer
GENOTROPIN PRESERVATIVE FREEApproved
somatropin
Pfizer
injection1995

Competitive Landscape

37 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
1
1
1
SomatropinPhase 2/31 trial
linezolidPhase 15 trials
Active Trials
NCT05007821Completed138Est. Jan 2026
NCT03828201Active Not Recruiting271Est. May 2027
NCT01356472Unknown60
+3 more trials
Bayer
BayerLEVERKUSEN, Germany
1 program
1
1
CiprofloxacinPhase 3Small Molecule1 trial
Active Trials
NCT00668044Completed18Est. Nov 2003
Sharp Therapeutics
1
Ceftolozane/tazobactamPhase 4
MSD
MSDIreland - Ballydine
1 program
1
Ceftolozane/tazobactamPhase 4
Cerus
CerusCA - Concord
1 program
1
Pathogen-Reduced PlasmaPhase 41 trial
Active Trials
NCT04681638Terminated13Est. Sep 2024
AVITA Medical
AVITA MedicalCA - Valencia
1 program
1
RECELLPhase 45 trials
Active Trials
NCT05971381Completed109Est. Jan 2025
NCT05386368Terminated1Est. May 2024
NCT04271501Terminated5Est. Aug 2021
+2 more trials
CellTherX
CellTherXTX - Dallas
1 program
1
Split thickness skin graftPhase 41 trial
Active Trials
NCT04589442Recruiting20Est. Dec 2021
Cumberland Pharmaceuticals
1
CaldolorPhase 31 trial
Active Trials
NCT00606489Completed61Est. May 2009
Baxter
BaxterCosta Rica - Cartago
1 program
1
I-020502Phase 21 trial
Active Trials
NCT00471939Completed10Est. Jan 2009
Biocorp
3 programs
1
human umbilical cord mesenchymal stem cellsPhase 1/2
BCT Antimicrobial DressingN/A1 trial
FlamazineN/A1 trial
Active Trials
NCT01598493Completed30Est. Mar 2014
NCT01598480Completed30Est. Mar 2014
Vomaris Innovations
1
ProcelleraPhase 1/21 trial
Active Trials
NCT01061502Completed17Est. Nov 2010
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
ST266Phase 1/2
Noveome Biotherapeutics
1 program
1
ST266Phase 1/21 trial
Active Trials
NCT00886470Terminated16Est. Mar 2010
Aegle Therapeutics
1
AGLE-102Phase 11 trial
Active Trials
NCT05078385Completed1Est. Nov 2024
Innovation Pharmaceuticals
1 program
1
Integra®Phase 11 trial
Active Trials
NCT05344521Not Yet Recruiting29Est. Feb 2027
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
Lactulose and Mannitol solutionPhase 11 trial
Active Trials
NCT03242434Terminated18Est. Mar 2018
Neomatrix
1 program
1
cNP8Phase 11 trial
Active Trials
NCT06223009Completed32Est. Jul 2024
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
3 programs
Fresh Frozen PlasmaN/A1 trial
Suprathel or Xeroform donor site applicationN/A1 trial
triple antibiotic ointment dressingN/A1 trial
Active Trials
NCT05069922Completed59Est. Aug 2025
NCT04014400Terminated10Est. Jul 2020
NCT02681757Completed96Est. Sep 2017
Cutiss
3 programs
EHSG-KFPHASE_21 trial
EHSG-KFPHASE_21 trial
denovoSkinPHASE_31 trial
Active Trials
NCT03229564Active Not Recruiting12Est. Jun 2028
NCT03227146Active Not Recruiting14Est. Dec 2025
NCT06745557Recruiting70Est. Jun 2028
Carbon Biosciences
Carbon BiosciencesMA - Waltham
2 programs
BCT Antimicrobial DressingN/A
FlamazineN/A
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
Biodegradable Temporizing MatrixN/A1 trial
Face-to-face burn careN/A1 trial
Active Trials
NCT02905435Completed15Est. Sep 2019
NCT05019144Completed130Est. Mar 2024
PolyNovo
PolyNovoAustralia - Port Melbourne
2 programs
Biodegradable Temporizing MatrixN/A
NovoSorb BTMN/A1 trial
Active Trials
NCT04090424Active Not Recruiting150Est. Dec 2026
MTI
MTIUT - Salt Lake City
2 programs
Proprioceptive neuromuscular facilitationN/A1 trial
Russian current and muscle energy techniquesN/A1 trial
Active Trials
NCT07183943Completed150Est. Jan 2026
NCT07174232Completed100Est. Jan 2026
Arrowhead Pharmaceuticals
1 program
Difference in development of Acute Lung Injury in Amphetamine positive and negative patientsN/A1 trial
Active Trials
NCT05611385Completed49Est. Jan 2020
Kerecis
KerecisIceland - Isafjordur
1 program
Fish skinN/A1 trial
Active Trials
NCT03984331Completed5Est. Sep 2021
Bristol Myers Squibb
1 program
Fluid Shifts During Resuscitation: Impacts on Macrocirculation and MicrocirculationN/A1 trial
Active Trials
NCT00326729Unknown40
Medtronic
MedtronicNJ - Phillipsburg
1 program
Kerlix AMD gauzeN/A1 trial
Active Trials
NCT00656708Completed108Est. Jan 2011
Integra LifeSciences
Integra LifeSciencesAustralia - Clayton
1 program
MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEYN/A1 trial
Active Trials
NCT02250183Terminated21Est. Aug 2016
Zimmer Biomet
Zimmer BiometFL - Jacksonville
1 program
With PRPN/A1 trial
Active Trials
NCT00858442Completed44Est. Nov 2012
Martin Pharmaceuticals
virtual realityN/A1 trial
Active Trials
NCT06596837Completed71Est. Aug 2023

+7 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AVITA MedicalRECELL
CerusPathogen-Reduced Plasma
CellTherXSplit thickness skin graft
AVITA MedicalRECELL
AVITA MedicalRECELL
Fresenius KabiVolulyte
Pfizerlinezolid
CutissdenovoSkin
Cumberland PharmaceuticalsCaldolor
BayerCiprofloxacin
Pfizerlinezolid
PfizerSomatropin
Pfizerlinezolid
Pfizerlinezolid
CutissEHSG-KF

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 9,763 patients across 50 trials

RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients

Start: Mar 2023Est. completion: May 20241 patients
Phase 4Terminated
NCT04681638CerusPathogen-Reduced Plasma

Plasma Resuscitation Without Lung Injury

Start: Aug 2022Est. completion: Sep 202413 patients
Phase 4Terminated
NCT04589442CellTherXSplit thickness skin graft

Microsurfaced Grafts in Deep Burn Wounds

Start: Jan 2021Est. completion: Dec 202120 patients
Phase 4Recruiting

Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients

Start: May 2015Est. completion: Jan 201610 patients
Phase 4Completed

A Pilot Trial of the Use of ReCell® Autologous Cell Harvesting Device for Venous Leg Ulcers

Start: Jan 2013Est. completion: Oct 201552 patients
Phase 4Completed

Fluid Resuscitation in Patients Suffering From Burns Injury

Start: Dec 2012Est. completion: Sep 201311 patients
Phase 4Terminated

Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia

Start: Jun 201160 patients
Phase 4Unknown

Phase III Study with an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents

Start: Dec 2024Est. completion: Jun 202870 patients
Phase 3Recruiting

Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients

Start: Nov 2007Est. completion: May 200961 patients
Phase 3Completed
NCT00668044BayerCiprofloxacin

Ciprofloxacin on Burned Patients

Start: Nov 2002Est. completion: Nov 200318 patients
Phase 3Completed

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

Start: Nov 2001Est. completion: Nov 2002120 patients
Phase 3Completed

Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients

Start: Nov 2015Est. completion: Nov 202113 patients
Phase 2/3Completed

Linezolid Dosing Strategies in Drug-Resistant TB

Start: Sep 2022Est. completion: Jan 2026138 patients
Phase 2Completed

Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB

Start: Jun 2022Est. completion: May 2027271 patients
Phase 2Active Not Recruiting

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children

Start: Oct 2017Est. completion: Jun 202812 patients
Phase 2Active Not Recruiting

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents

Start: Oct 2017Est. completion: Dec 202514 patients
Phase 2Active Not Recruiting
NCT00812513Johnson & JohnsonR-Pdf/Gbb 0.01% gel

Efficacy of R-Pdf/Gbb in Healing Wounds Caused by Third Degree Thermal and Electrical Burns

Start: Jul 2011Est. completion: Apr 2012120 patients
Phase 2Unknown

Safety and Efficacy of I-020502 in Meshed Skin Autografting

Start: Apr 2007Est. completion: Jan 200910 patients
Phase 2Completed

Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds

Start: Sep 2009Est. completion: Nov 201017 patients
Phase 1/2Completed

ST266 Versus Standard Care In Treating Partial Thickness Burns

Start: Jun 2009Est. completion: Mar 201016 patients
Phase 1/2Terminated

A Phase I, Single-blind, Randomized Study of the Safety and Efficacy of Cellularized Integra® Using Autologous Burn-derived Stem Cells

Start: Feb 2024Est. completion: Feb 202729 patients
Phase 1Not Yet Recruiting

Phase 1 Healthy Volunteer Burn Therapy Study

Start: Jan 2024Est. completion: Jul 202432 patients
Phase 1Completed

Safety of Extracellular Vesicles for Burn Wounds

Start: Aug 2023Est. completion: Nov 20241 patients
Phase 1Completed
NCT03242434ViiV HealthcareLactulose and Mannitol solution

Investigation of Thermal Injury on Intestinal Permeability in Both Thermal Injury and Healthy Participants

Start: Jan 2018Est. completion: Mar 201818 patients
Phase 1Terminated

Evaluation Of Linezolid Pk Profile In Burns Patients

Start: May 2006Est. completion: Jan 200716 patients
Phase 1Completed
NCT07183943MTIProprioceptive neuromuscular facilitation

VR Gaming Based PNF on Spatiotemporal Parameters in Upper Limb Burned Patients

Start: Oct 2025Est. completion: Jan 2026150 patients
N/ACompleted
NCT07174232MTIRussian current and muscle energy techniques

Russian Current and Muscle Energy Techniques on Circumferential Upper Arm Burn

Start: Oct 2025Est. completion: Jan 2026100 patients
N/ACompleted

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

Start: Aug 2023Est. completion: Jan 2025109 patients
N/ACompleted
NCT05019144Human BioSciencesFace-to-face burn care

Telemedicine Optimized Burn Intervention

Start: Jun 2022Est. completion: Mar 2024130 patients
N/ACompleted

Randomized Trial of Fresh Frozen Plasma Versus Albumin in Acute Burn Resuscitation

Start: Feb 2022Est. completion: Aug 202559 patients
N/ACompleted

Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns

Start: Sep 2021Est. completion: Dec 2026150 patients
N/AActive Not Recruiting

Virtual Reality and Coping with Procedural Pain in Burn Patients

Start: Sep 2021Est. completion: Aug 202371 patients
N/ACompleted

Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions

Start: Sep 2020Est. completion: Aug 20215 patients
N/ATerminated

Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions

Start: Sep 2020Est. completion: Jan 202325 patients
N/ACompleted

RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years

Start: Mar 2020Est. completion: Jun 202219 patients
N/ATerminated

RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction

Start: Mar 2020Est. completion: Feb 202365 patients
N/ACompleted
NCT04014400Colorado TherapeuticsSuprathel or Xeroform donor site application

Suprathel Versus Xeroform for the Management of Skin Graft Donor Sites

Start: Jul 2019Est. completion: Jul 202010 patients
N/ATerminated

Fish Skin Compared to Cadaver Skin as Temporary Cover for Full Thickness Burns

Start: Feb 2019Est. completion: Sep 20215 patients
N/ACompleted
NCT05611385Arrowhead PharmaceuticalsDifference in development of Acute Lung Injury in Amphetamine positive and negative patients

Amphetamine Induced Adult Respiratory Distress Syndrome

Start: Jan 2019Est. completion: Jan 202049 patients
N/ACompleted

RES Prepared With RECELL® Compared to Conventional Care for Healing of Donor Sites in Ages 1-16 Years

Start: Sep 2018Est. completion: Jan 20203 patients
N/ATerminated

Continued Access to the Recell® Device for Treatment of Acute Burn Injuries

Start: Oct 2017Est. completion: May 201976 patients
N/ACompleted
NCT02905435Human BioSciencesBiodegradable Temporizing Matrix

Assessment of Safety and Effectiveness of Biodegradable Temporizing Matrix in the Treatment of Deep Burn Skin Injuries

Start: Nov 2016Est. completion: Sep 201915 patients
N/ACompleted

CONTINUED ACCESS PROTOCOL: Demonstration of the Safety and Effectiveness of ReCell® Combined With Meshed Skin Graft for Reduction of Donor Area in the Treatment of Acute Burn Injuries

Start: Oct 2016Est. completion: Sep 201812 patients
N/ACompleted
NCT02681757Colorado Therapeuticstriple antibiotic ointment dressing

Comparison of Mepitel Ag vs Antibiotic Ointment Used With Soft Cast Technique for Treatment of Pediatric Burns

Start: Sep 2016Est. completion: Sep 201796 patients
N/ACompleted

ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries

Start: Jan 2015Est. completion: Feb 201730 patients
N/ACompleted

Prospective Evaluation of the ReCell® Autologous Cell Harvesting Device For Specific Compassionate Use Cases

Start: May 2014Est. completion: Jun 2020100 patients
N/ACompleted
NCT02250183Integra LifeSciencesMEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY

Medihoney and Santyl for Burn Injuries

Start: Mar 2014Est. completion: Aug 201621 patients
N/ATerminated
NCT01598493BiocorpBCT Antimicrobial Dressing

To Study the Healing Effect of Silver Impregnated Activated Carbon Fiber Wound Dressing on Deep Dermal Burn

Start: May 2012Est. completion: Mar 201430 patients
N/ACompleted

To Study the Healing Effect of Silver Impregnated Activated Carbon Fiber Wound Dressing on Superficial Dermal Burn

Start: May 2012Est. completion: Mar 201430 patients
N/ACompleted

Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients

Start: May 2011Est. completion: May 20127,260 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 9,763 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.